Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.83 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.70 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.70 |
| ▸ | CDK1 | P06493 | 1/20 | 0.70 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.70 |
| ▸ | FLT1 | P17948 | 1/20 | 0.70 |
| ▸ | MARK3 | P27448 | 1/20 | 0.70 |
| ▸ | KDR | P35968 | 1/20 | 0.70 |
| ▸ | FLT3 | P36888 | 1/20 | 0.70 |
| ▸ | CLK2 | P49760 | 1/20 | 0.70 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.70 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.70 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.70 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.70 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.70 |
| ▸ | PHKG1 | Q16816 | 1/20 | 0.70 |
| ▸ | MAPK15 | Q8TD08 | 1/20 | 0.70 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.70 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL617809 | 1.00 | CHEK1 (1.00) | CHEK1KCNH2NUAK1CHEK2CDK1 | |
| SCHEMBL30644886 | 1.00 | CHEK1 (1.00) | CHEK1KCNH2NUAK1CHEK2CDK1 | |
| SCHEMBL12123063 | 0.91 | CHEK1 (0.84) | CHEK1KCNH2 | |
| SCHEMBL30644885 | 0.91 | CHEK1 (1.00) | CHEK1KCNH2 | |
| SCHEMBL618209 | 0.91 | CHEK1 (1.00) | CHEK1KCNH2 | |
| SCHEMBL618210 | 0.91 | CHEK1 (1.00) | CHEK1KCNH2 | |
| SCHEMBL617670 | 0.90 | CHEK1 (1.00) | CHEK1KCNH2CHEK2 | |
| SCHEMBL10172570 | 0.90 | CHEK1 (0.84) | CHEK1KCNH2 | |
| SCHEMBL30644881 | 0.90 | CHEK1 (1.00) | CHEK1KCNH2CHEK2 | |
| SCHEMBL620064 | 0.90 | CHEK1 (1.00) | CHEK1KCNH2CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787792-B2 | 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2 Pyridyl]Amino]Pyrazine-2-carbonitrile and therapeutic uses thereof | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
| US-11787792-B2 | 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2 Pyridyl]Amino]Pyrazine-2-carbonitrile and therapeutic uses thereof | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
| US-20210276990-A1 | 5-[[4-[[Morpholin-2-yl]Methylamino]-5-(Trifluoromethyl)-2 Pyridyl]Amino]Pyrazine-2-Carbonitrile and Therapeutic Uses Thereof | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-09-09 | — | — | US | disclosed |
| US-10259806-B2 | 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2 pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-04-16 | — | — | US | disclosed |
| US-20180022739-A1 | 5-[[4-[[Morpholin-2-yl]Methylamino]-5-(Trifluoromethyl)-2 Pyridyl]Amino]Pyrazine-2-Carbonitrile and Therapeutic Uses Thereof | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-20180022739-A1 | 5-[[4-[[Morpholin-2-yl]Methylamino]-5-(Trifluoromethyl)-2 Pyridyl]Amino]Pyrazine-2-Carbonitrile and Therapeutic Uses Thereof | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-9663503-B2 | 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-05-30 | — | — | US | disclosed |
| US-9663503-B2 | 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-05-30 | — | — | US | disclosed |
| EP-2855448-B1 | 5-[[4-[[MORPHOLIN-2-YL]METHYLAMINO]-5-(TRIFLUOROMETHYL)-2-PYRIDYL]AMINO]PYRAZINE-2-CARBONITRILE AND THERAPEUTIC USES THEREOF | CANCER RES TECH LTD (GB) | 2017-02-08 | — | — | EP | disclosed |
| EP-2197874-B1 | PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2016-08-31 | — | — | EP | disclosed |
| US-20120040967-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-8058045-B2 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-11-15 | — | — | US | disclosed |
| US-8058045-B2 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-11-15 | — | — | US | disclosed |
| US-8058045-B2 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-11-15 | — | — | US | disclosed |
| US-20100311730-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-12-09 | — | — | US | disclosed |
| US-20100311730-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-12-09 | — | — | US | disclosed |
| US-20100311730-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-12-09 | — | — | US | disclosed |
| EP-2197874-A1 | PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009044162-A1 | PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009044162-A1 | PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022739-A1 | 5-[[4-[[Morpholin-2-yl]Methylamino]-5-(Trifluoromethyl)-2 Pyridyl]Amino]Pyrazine-2-Carbonitrile and Therapeutic Uses Thereof | CHEK1, CHEK2, BUB1B | CHEK1 1/4885KCNH2 4073/4885NUAK1 1026/4885 |
| US-20210276990-A1 | 5-[[4-[[Morpholin-2-yl]Methylamino]-5-(Trifluoromethyl)-2 Pyridyl]Amino]Pyrazine-2-Carbonitrile and Therapeutic Uses Thereof | CHEK1, CHEK2, BUB1B | CHEK1 1/4885KCNH2 4073/4885NUAK1 1026/4885 |
| US-11787792-B2 | 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2 Pyridyl]Amino]Pyrazine-2-carbonitrile and therapeutic uses thereof | CHEK1, CHEK2, BUB1B | CHEK1 1/4885KCNH2 4073/4885NUAK1 1026/4885 |
| US-10259806-B2 | 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2 pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof | CHEK1, CHEK2, CDK1 | CHEK1 1/4885KCNH2 4384/4885NUAK1 993/4885 |
| US-20120040967-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CHEK1, CHEK2, PLK1 | CHEK1 1/4885KCNH2 2862/4885NUAK1 484/4885 |
| US-20100311730-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CHEK1, CHEK2, BUB1B | CHEK1 1/4885KCNH2 1449/4885NUAK1 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.